AbbVie Inc. $ABBV Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC reduced its stake in AbbVie Inc. (NYSE:ABBV) by 28.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 439,478 shares of the company’s stock after selling 171,116 shares during the period. Allspring Global Investments Holdings LLC’s holdings in AbbVie were worth $100,777,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Diversified Trust Co raised its stake in shares of AbbVie by 23.6% in the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after acquiring an additional 10,891 shares in the last quarter. Permanent Capital Management LP acquired a new stake in AbbVie in the 3rd quarter valued at about $720,000. Railway Pension Investments Ltd raised its position in AbbVie by 33.0% in the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after purchasing an additional 211,800 shares in the last quarter. World Investment Advisors boosted its stake in shares of AbbVie by 9.4% in the 3rd quarter. World Investment Advisors now owns 113,925 shares of the company’s stock valued at $26,378,000 after buying an additional 9,811 shares during the period. Finally, Charles Schwab Trust Co boosted its stake in shares of AbbVie by 93.4% in the 3rd quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock valued at $7,434,000 after buying an additional 15,502 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Earnings momentum and guidance: AbbVie posted a quarterly EPS beat and raised FY‑2026 guidance earlier this year, which supports investor confidence in near‑term earnings and cash flow (background company report).
• Positive Sentiment: Analyst support: BMO (via TipRanks coverage) maintained a Buy rating and $258 price target, reinforcing bullish sentiment among institutional investors. AbbVie: Immunology Strength, Strategic Acquisitions, and Patent Headwind Execution Support Buy Rating
• Positive Sentiment: Institutional buying: Beacon Investment Advisory increased its stake in ABBV, signaling continued institutional interest. Beacon Investment Advisory Services Inc. Has $19.86 Million Stock Position in AbbVie Inc. $ABBV
• Positive Sentiment: Aesthetics business activity: Allergan Aesthetics (an AbbVie unit) launched promotional CoolMonth offers and presented safety/efficacy data at AAD — both support the aesthetics revenue story. Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting® Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 AAD
• Positive Sentiment: Macro tax tailwind: Analysis shows corporate cash taxes fell materially under the new tax law, a factor that can boost free cash flow for large pharma including AbbVie. US Corporate Taxes Drop $65 Billion After Trump’s $3.4 Trillion Tax Law
• Neutral Sentiment: Stock commentary: MarketWatch notes ABBV rose but still slightly underperformed the broader market on the day; useful context for relative performance. AbbVie Inc. stock rises Tuesday, still underperforms market
• Neutral Sentiment: Upcoming event: AbbVie set its Q1 2026 earnings release and conference call for April 29 — an event that could drive volatility and provide fresh guidance. AbbVie to Host First-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Competitive messaging: AbbVie publicly defends Skyrizi’s efficacy edge as J&J launches Icotyde — shows competitive dynamics in immunology/dermatology but not an immediate structural change. As J&J Brings Icotyde to Market, AbbVie Remains Confident in Skyrizi’s Efficacy Edge
• Negative Sentiment: Oncology pressure: Analyst coverage (Zacks) highlights 2026 headwinds for AbbVie’s oncology revenue — Imbruvica pricing pressure may weigh on top‑line growth despite newer drug contributions. Will AbbVie’s Oncology Drugs Aid Top Line in 2026?
• Negative Sentiment: Lawsuit tied to Cerevel deal: A Bloomberg Law item says investors’ suit over the Cerevel deal involving Pfizer/Bain must proceed, which could raise legal risk/uncertainty around the transaction and reputational exposure. Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit
• Negative Sentiment: Peer M&A strengthens competition: Merck’s large oncology deal (Terns) reinforces competitive pressure in oncology — a potential headwind for AbbVie’s oncology growth narrative. Merck Just Made a Big Bet on a New Cancer Growth Engine

Insider Transactions at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.08% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of recent research reports. Piper Sandler upped their target price on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Barclays started coverage on shares of AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target for the company. Evercore decreased their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. UBS Group dropped their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Finally, William Blair restated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Stock Up 2.0%

Shares of AbbVie stock opened at $217.39 on Wednesday. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The firm’s 50 day moving average is $222.00 and its two-hundred day moving average is $224.65. The firm has a market capitalization of $384.38 billion, a P/E ratio of 92.11, a P/E/G ratio of 0.74 and a beta of 0.34.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the previous year, the firm earned $2.16 EPS. The company’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.